多西环素暴露后预防与B群脑膜炎球菌疫苗预防法国细菌性性传播感染(ANRS 174 DOXYVAC):一项2×2析因设计的多中心、开放标签、随机试验
ANRS 174 DOXYVAC试验在法国巴黎10家医院纳入556名有细菌性性传播感染史的HIV阴性男男性行为者,随机分配至多西环素暴露后预防(2:1)和4CMenB疫苗(1:1)组。多西环素暴露后预防组衣原体或梅毒(或两者)首次发作发生率显著低于无暴露后预防组(aHR 0.17,95%CI 0.12-0.26;p<0.0001),4CMenB疫苗对淋病发病率未见显著效果(aHR 0.78,95%CI 0.60-1.01;p=0.061)。
要点
- 多西环素暴露后预防显著降低MSM衣原体或梅毒(或两者)首次发作风险,aHR 0.17(95%CI 0.12-0.26;p<0.0001)。
- 4CMenB疫苗对淋病发病率未见显著效果,aHR 0.78(95%CI 0.60-1.01;p=0.061)。
- 多西环素暴露后预防组出现1例药物相关严重不良事件(固定性药疹),6例(2%)因胃肠道不良事件停药。
核心结论
- 多西环素暴露后预防强烈降低MSM衣原体和梅毒发病率,但未显示4CMenB疫苗对淋病的有效性。
- 作者认为多西环素暴露后预防应在其他人群(如异性恋男性和女性)中评估,并仔细监测其对 antimicrobial resistance 的影响。
研究设计与样本
- ANRS 174 DOXYVAC为在法国巴黎10家医院开展的多中心、开放标签、2×2析因设计随机试验。
- 纳入标准:18岁及以上、HIV阴性、入组前12个月内有过细菌性性传播感染史、已纳入ANRS PREVENIR研究(使用替诺福韦和恩曲他滨暴露前预防HIV的MSM队列)的MSM。
- 随机分配:多西环素暴露后预防组与无暴露后预防组按2:1随机;4CMenB疫苗组与无疫苗组按1:1随机;使用计算机生成的随机化列表,固定区组大小为4。
- 干预措施:多西环素暴露后预防为无保护性行为后72小时内口服两片100mg药片,每周不超过三次200mg剂量;4CMenB疫苗(GlaxoSmithKline,巴黎,法国)为入组时和2个月时各肌肉注射一剂。
- 随访至少12个月(每3个月访视一次),最长至24个月;共同主要终点为多西环素干预组基线访视后衣原体或梅毒(或两者)首次发作风险,以及疫苗干预组从第3个月(即第二剂疫苗后1个月)起淋病首次发作风险,在改良意向治疗人群(所有随机分配且至少有一次随访访视的参与者)中分析。
主要发现
- 2021年1月19日至2022年9月19日期间,共随机分配556名参与者;多西环素暴露后预防组与无暴露后预防组的改良意向治疗分析纳入545名(98%)参与者,4CMenB疫苗组与无疫苗组纳入544名(98%)参与者。
- 中位随访时间为14个月(IQR 9-18);中位年龄为40岁(34-48);545名参与者全部为男性。
- 两种干预措施对主要结局无交互作用(p≥0.1)。
- 多西环素暴露后预防组衣原体或梅毒(或两者)首次发作发生率为8.8/100人年(362名参与者中35起事件),无暴露后预防组为53.2/100人年(183名参与者中80起事件);调整后风险比(aHR)0.17(95%CI 0.12-0.26;p<0.0001)。
- 从第3个月起,4CMenB疫苗组淋病首次发作发生率为58.3/100人年(274名参与者中103起事件),无疫苗组为77.1/100人年(270名参与者中122起事件);aHR 0.78(95%CI 0.60-1.01;p=0.061)。
关键数值与推荐
- 多西环素暴露后预防组衣原体或梅毒(或两者)首次发作发生率8.8/100人年 vs 无暴露后预防组53.2/100人年,aHR 0.17(95%CI 0.12-0.26;p<0.0001)。
- 4CMenB疫苗组淋病首次发作发生率58.3/100人年 vs 无疫苗组77.1/100人年,aHR 0.78(95%CI 0.60-1.01;p=0.061)。
临床怎么用
- 作者认为多西环素暴露后预防应在其他人群(如异性恋男性和女性)中评估,并仔细监测其对抗菌药物耐药性的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased rates of sexually transmitted infections (STIs) are reported among men who have sex with men (MSM) and new interventions are needed. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of chlamydia or syphilis (or both) and whether the meningococcal group B vaccine (4CMenB) could reduce the incidence of gonorrhoea in this population. METHODS: ANRS 174 DOXYVAC is a multicentre, open-label, randomised trial with a 2 × 2 factorial design conducted at ten hospital sites in Paris, France. Eligible participants were MSM aged 18 years or older, HIV negative, had a history of bacterial STIs within the 12 months before enrolment, and who were already included in the ANRS PREVENIR study (a cohort of MSM using pre-exposure prophylaxis with tenofovir and emtricitabine for HIV prevention). Participants were randomly assigned (2:1) to doxycycline PEP (two pills of 100 mg each orally within 72 h after condomless sex, with no more than three doses of 200 mg per week) or no PEP groups and were also randomly assigned (1:1) to the 4CMenB vaccine (GlaxoSmithKline, Paris, France; two intramuscular injections at enrolment and at 2 months) or no vaccine groups, using a computer-generated randomisation list with a permuted fixed block size of four. Follow-up occurred for at least 12 months (with visits every 3 months) up to 24 months. The coprimary outcomes were the risk of a first episode of chlamydia or syphilis (or both) after the enrolment visit at baseline for the doxycycline intervention and the risk of a first episode of gonorrhoea starting at month 3 (ie, 1 month after the second vaccine dose) for the vaccine intervention, analysed in the modified intention-to-treat population (defined as all randomly assigned participants who had at least one follow-up visit). This trial is registered with ClinicalTrials.gov, NCT04597424 (ongoing). FINDINGS: Between Jan 19, 2021, and Sept 19, 2022, 556 participants were randomly assigned. 545 (98%) participants were included in the modified intention-to-treat analysis for the doxycycline PEP and no PEP groups and 544 (98%) were included for the 4CMenB vaccine and no vaccine groups. The median follow-up was 14 months (IQR 9-18). The median age was 40 years (34-48) and all 545 participants were male. There was no interaction between the two interventions (p≥0·1) for the primary outcome. The incidence of a first episode of chlamydia or syphilis (or both) was 8·8 per 100 person-years (35 events in 362 participants) in the doxycycline PEP group and 53·2 per 100 person-years (80 events in 183 participants) in the no PEP group (adjusted hazard ratio [aHR] 0·17 [95% CI 0·12-0·26]; p<0·0001). The incidence of a first episode of gonorrhoea, starting from month 3 was 58·3 per 100 person-years (103 events in 274 participants) in the 4CmenB vaccine group and 77·1 per 100 person-years (122 events in 270 participants) in the no vaccine group (aHR 0·78 [95% CI 0·60-1·01]; p=0·061). There were no deaths during the study. One drug-related serious adverse event (fixed-drug eruption) occurred in the doxycycline PEP group. Six (2%) participants in the doxycycline group discontinued doxycycline PEP because of gastrointestinal adverse events. INTERPRETATION: Doxycycline PEP strongly reduced the incidence of chlamydia and syphilis in MSM, but we did not show efficacy of the 4CmenB vaccine for gonorrhoea. Doxycycline PEP should be assessed in other populations, such as heterosexual men and women, and its effect on antimicrobial resistance carefully monitored. FUNDING: ANRS Maladies Infectieuses Emergentes. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Molina JM, Bercot B, Assoumou L, et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis. 2024. PMID: 38797183. doi:10.1016/S1473-3099(24)00236-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。